Skip to content

Bioscience PhD Programs

Main Navigation

Ami Patel

Assistant Professor of Hematology and Adjunct Assistant Professor of Oncological Sciences

Leukemia, myeloid malignancies, cancer biology, stem cell, myeloproliferative disease

Patel Photo

Molecular Biology Program

Education

B.S. Northwestern University

M.D. Feinberg School of Medicine, Northwestern University

Links

Lab Page

PubMed Literature Search

ami.patel@hci.utah.edu

Research

I am a hematologist-oncologist and physician-scientist with an independent translational research program investigating the molecular biology of myeloid malignancies, specifically myeloid leukemogenesis as it relates to the intersection of inflammation, aging and oncogenic kinase signaling. My clinical practice encompasses the diagnosis and treatment of myelodysplastic/myeloproliferative (MDS/MPN) overlap disorders, myeloproliferative neoplasms(MPNs), and acute myeloid leukemia (AML). My research focuses on understanding cell signaling in myeloid leukemias and the molecular mechanisms governing drug resistance to targeted agents in these diseases. My laboratory-based research complements my clinical practice by informing novel treatment strategies for implementation in early-phase clinical trials - with the goal of rapidly translating relevant preclinical findings and improving outcomes for leukemia patients. My laboratory has specific expertise in studying resistance mechanisms to kinase inhibitors that act upon oncogenic kinases such as MEK1/2, BCR-ABL1, JAK2 and FLT3-ITD. Previously, I found that resistance to the FLT3 inhibitor quizartinib is mediated through soluble factors secreted by bone marrow stromal cells in AML (Patel et al, Leukemia, 2020). I also led the effort to functionally characterize a novel JAK2 insertion-deletion mutant associated with resistance to JAK2 inhibition and clinical features of both polycythemia and hypereosinophilia (Patel et al, Blood, 2019). I am the principal investigator on an investigator-initiated trial (NCT04409639) of the MEK inhibitor cobimetinib in RAS/MAPK-activated chronic myelomonocytic leukemia (CMML) that will help define the efficacy of RAS/MAPK inhibition in this disease and elucidate mechanisms of resistance to oncogenic RAS/MAPK signaling in myeloid leukemias.

References

Selected publications:

  1. Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel AB. Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. Leuk Res Rep. 2025 Aug 25;24:100541. doi: 10.1016/j.lrr.2025.100541. PMID: 40917153; PMCID: PMC12409799.
  2. Arellano NS, Heaton WL, Nauman MC, Runnels AE, Gomez-Villa J, Vanni D, Gaviria M, Fujita M, Krah NM, Ciboddo M, Yadav S, Brown CT, Bowden PD, Chen AK, Henning C, Catricalà S, Casetti IC, Borsani O, Rumi E, Pietra D, Plo I, Marty C, Marchetti M, Patel AB, Saygin C, Elf SE. Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood. 2025 Aug 21;146(8):971-983.
  3. Zhukovsky S, Rets A, Braaten T, Patel AB. VEXAS without vacuoles: Linking genotype to phenotype. EJHaem. 2024 Oct 5;5(5):981-986. doi: 10.1002/jha2.1016. PMID: 39415928; PMCID: PMC11474288.
  4. Vardell VA, Ose J, Rets AV, Tantravahi SK, Patel AB. Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis. Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):843-851. doi: 10.1016/j.clml.2024.07.013. Epub 2024 Jul 31. PMID: 39179449.
  5. Krah NM, Miotke L, Li P, Patel JL, Bowen AR, Pomicter AD, Patel AB. JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome. J Natl Compr Canc Netw. 2023 Dec;21(12):1218-1223. doi: 10.6004/jnccn.2023.7068. PMID: 38081125.
  6. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger MW. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia. 2020 Nov;34(11):2981-2991. doi: 10.1038/s41375-020-0858-1. Epub 2020 May 14. PMID: 32409689; PMCID: PMC7606260.
  7. Patel AB*, Franzini A*, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, O'Hare T, Prchal JT, Deininger MW. JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood. 2019 Dec 26;134(26):2388-2398. doi: 10.1182/blood.2019001385. PMID: 31697804; PMCID: PMC6933291.
  8. Patel AB, Miles RR, Deininger MW. Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep. 2019 May 10;7(6):1263-1264. doi: 10.1002/ccr3.2188. PMID: 31183108; PMCID: PMC6553339.
  9. Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW. Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv. 2019 Apr 9;3(7):952-955. doi: 10.1182/bloodadvances.2019032300. PMID: 30923049; PMCID: PMC6457233.
  10. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18. PMID: 30563936; PMCID: PMC6445677.
  11. Patel AB, Lange T, Pomicter AD, Conley CJ, Harrington CA, Reynolds KR, Kelley TW, O'Hare T, Deininger MW. Similar expression profiles in CD34+cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget. 2018 Apr 3;9(25):17889-17894. doi: 10.18632/oncotarget.24954. PMID: 29707154; PMCID: PMC5915162.
Last Updated: 12/22/25